Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapirolizumab Pegol in Systemic Lupus Erythematosus
NCT06617325Phase 3Recruiting
- Sponsor
- UCB
- Start
- Nov 2024
- Primary completion
- May 2028
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Dapirolizumab pegol with Placebo (2 arms). Primary endpoint: BILAG 2004-based Composite Lupus Assessment at 48 weeks. Started Nov 2024; status: recruiting.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06617325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617325.